{"organizations": [], "uuid": "24e133d66cb65a69171b29725b9955d1c58730fb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kite-sangamo-therapeutics-announce/brief-kite-sangamo-therapeutics-announce-collaboration-to-develop-next-generation-engineered-cell-therapies-for-treatment-of-cancer-idUSFWN1QC0JE", "country": "US", "domain_rank": 408, "title": "BRIEF-Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.019, "site_type": "news", "published": "2018-02-22T20:16:00.000+02:00", "replies_count": 0, "uuid": "24e133d66cb65a69171b29725b9955d1c58730fb"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kite-sangamo-therapeutics-announce/brief-kite-sangamo-therapeutics-announce-collaboration-to-develop-next-generation-engineered-cell-therapies-for-treatment-of-cancer-idUSFWN1QC0JE", "ord_in_thread": 0, "title": "BRIEF-Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer", "locations": [], "entities": {"persons": [{"name": "kite", "sentiment": "none"}], "locations": [{"name": "allogeneic", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gilead", "sentiment": "negative"}, {"name": "sangamo therapeutics", "sentiment": "negative"}, {"name": "sangamo therapeutics inc", "sentiment": "negative"}, {"name": "sangamo", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "unce", "sentiment": "none"}, {"name": "kite", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Sangamo Therapeutics Inc:\n* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER\n* SANGAMO THERAPEUTICS - KITE TO RECEIVE EXCLUSIVE LICENSE TO LEVERAGE SANGAMOâ€˜S GENE EDITING TECHNOLOGY IN ALLOGENEIC AND AUTOLOGOUS CELL THERAPY PROGRAMS IN ONCOLOGY\n* SANGAMO THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION\n* SANGAMO THERAPEUTICS INC - UNDER TERMS, SANGAMO IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS\n* SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR AGREED UPON EXPENSES INCURRED BY SANGAMO\n* SANGAMO THERAPEUTICS INC - CO WOULD ALSO RECEIVE TIERED ROYALTIES ON SALES OF POTENTIAL FUTURE PRODUCTS RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T20:16:00.000+02:00", "crawled": "2018-02-23T15:44:04.000+02:00", "highlightTitle": ""}